The study, published in the British Journal of Cancer, observed poor survival at the end of the follow-up period in men carrying the mutation, compared to non-carriers.
BRCA2
Among men with prostate cancer detected on screening, survival among those with a mutation in the gene is much poorer than in those without such a mutation, researchers report.
BRCA2
British Journal of Cancer
The findings suggest that mutation carriers may warrant additional treatments to improve their prognosis, say Steven Narod (Women’s College Hospital, Toronto, Ontario) and fellow authors writing in the .
BRCA2
BRCA2
mutations are known to confer an increased risk for developing prostate cancer and also to be associated with more aggressive tumours. However, the effect of mutations status on mortality in the setting of screen-detected cancers is unclear.
Original report: http://bit.ly/1yRJII4
Source: medwireNews
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
QCCA, NCCA Merge to Form ONCare Among Independent Oncology Practices
February 29th 2024ONCare Alliance will be led by 2 of the leading women in community oncology, cochairs Barbara McAneny, MD, of the New Mexico Cancer Center, and Sibel Blau, MD, of Northwest Medical Specialties, PLLC, of Puyallup, Washington.
Read More